Review and Update of AMX0035 in the Treatment of ALS
Monday, October 19, 2020
12:00 PM - 1:00 PM
Online via zoom
Save the Date: AMX0035 Research Update by Dr. Elliott Oct. 19
“Review and Update of AMX0035 in the Treatment of ALS”
Monday, October 19, 2020 Noon-1 pm (Pacific)
Join Dr. Michael Elliott, Medical Director for the ALS Clinic at the Swedish Neuroscience Institute, for an update on a promising new drug by Amylyx. AMX0035 is an oral therapy dissolved in water that combines two existing drugs, sodium phenylbutyrate and taurursodiol. Trial results indicate the drug cocktail slowed ALS progression in a statistically meaningful and clinically relevant way and that the drug combination is generally safe and well-tolerated. The ALS Association and I AM ALS have launched a petition calling on the FDA and Amylyx Pharmaceuticals to bring AMX0035 to market as soon as possible. Learn more and sign the petition.